Efficacy vs BREO (an ICS/LABA) and vs ANORO (a LAMA/LABA)
Help patients with COPD breathe better today and reduce exacerbations tomorrow
TRELEGY was evaluated in 2 replicate studies vs BREO—and in IMPACT, a 52-week landmark study vs BREO and vs ANORO in 10,000+ patients with a history of COPD exacerbations1,2
RAPID
As early as 15 minutes1
TRELEGY is not a rescue inhaler and should not be used for the relief of acute symptoms.
TRELEGY provided improvement in FEV1 vs BREO, as measured by LS mean change from baseline in FEV1, beginning at 15 minutes on Day 1.1
LASTING
Maintained for 24 hours1
Improvement persisted for 24 hours on Day 1 and Day 84.1
In these 2 replicate studies, the primary efficacy endpoint was trough FEV1 at Day 85. The LS mean change from baseline in trough FEV1 at Day 85 for TRELEGY 100/62.5/25 (n=206 in each trial) vs placebo + BREO 100/25 (n=206 in each trial) was 124 mL for trial 1 and 122 mL for trial 2.1
TRELEGY helps prevent exacerbations
In patients with a history of COPD exacerbations:
Superior exacerbation rate reduction vs ANORO (a LABA/LAMA) & vs BREO (an ICS/LABA)2
Primary endpoint: annual rate of moderate to severe exacerbations2
.png?auto=format)
.png?auto=format)
Exacerbation severity criteria: Moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.
Improved lung function with TRELEGY
In patients with a history of COPD exacerbations:
Superior and sustained lung function improvement vs BREO (an ICS/LABA) & vs ANORO (a LABA/LAMA)2
Secondary and other endpoint:
change from baseline in trough FEV1 at Week 522,3


Superior improvement in quality of life with TRELEGY
- SGRQ is a validated, respiratory disease-specific, patient-reported instrument that assesses symptoms, activities, and impact on daily life domains4
- Responder rate is the percentage of patients with a response, defined as a decrease from baseline of 4 or more in SGRQ total score2
TRELEGY demonstrated superior improvement in quality of life vs BREO (an ICS/LABA) & vs ANORO (a LABA/LAMA)2
Responder rate was statistically significantly greater for TRELEGY2,3

Adverse events and additional safety information from the IMPACT trial (COPD)
The most commonly reported adverse events with ≥5% incidence from the 52‑week IMPACT trial2,3
|
TRELEGY 100/62.5/25 |
BREO |
ANORO 62.5/25 (n=2070) % |
Viral URTI |
13 |
12 |
11 |
COPD* |
11 |
11 |
13 |
URTI |
7 |
7 |
6 |
Pneumonia |
7 |
6 |
4 |
Headache |
6 |
5 |
5 |
*Signs, symptoms, or progression of COPD are more severe than expected for the subject's condition.
Pneumonia incidence as reported from adverse events of special interest from the 52-week IMPACT trial2
TRELEGY (n=4151) % |
BREO (n=4134) % |
ANORO 62.5/25 (n=2070) % |
8 |
7 |
5 |
Fatal pneumonia occurred in 12 of 4151 patients (0.35 per 100 patient-years) receiving TRELEGY 100/62.5/25; 5 of 4134 patients (0.17 per 100 patient-years) receiving BREO 100/25; and 5 of 2070 patients (0.29 per 100 patient-years) receiving ANORO.
Want to see local coverage for TRELEGY vs other therapies?